En Es
Products
Covid-19
Companies
Pre-Owned
News
Events
About Us       Join now!
Categories

Browse Products by Category

Critical Care

Emergency Medicine

Intensive Care

Respiratory Care

Anesthesiology Systems

Home Care

Rehabilitation

Other

Hospital Infrastructure

IT Equipment

Transportation Systems

Other

Medical Imaging

Computed Tomography

Digital Radiography

Image Management Systems

Interventional Radiology

Magnetic Resonance Imaging

Mammography

PACS/RIS

Positron Emission Tomography

Radiation Safety

Radiography

Single-Photon Emission Computed Tomography

Ultrasound

Other

Patient Care

Bariatric Care

Beds

Examination Equipment

Other

Surgery

Endoscopy

Laparoscopy

Laser Surgery

Operating Room Equipment

Sterilization

Surgical Implants

Surgical Instruments

Waste Management

Other

Clinical Laboratory

Blood/Gas Analyzers

Cell Counters

Centrifuges

Clinical Chemistry Analyzer

Coagulation Analyzers

General Lab

Hematology Analyzers

Immunoassay Systems

Lab Glassware

Microplate Reader

Microscopes

Pipettes

Rapid Tests

Ready-to-use Kits for Analysis

Urine Analyzer

Other

Browse Products by Category

Close

Luminex Corporation

Luminex develops, manufactures, and markets biological testing technologies with applications in clinical diagnostics, pharmaceutical drug discovery, biomedical research, including genomic and proteomic research, personalized medicine, biodefense research, and food safety. The company’s open-architecture xMAP technolog ...
Products Covid-19NewsSummary
Close

Covid-19 Luminex Corporation

Clinical Laboratory

Respiratory Assay
VERIGENE ll Respiratory Flex Assay

The VERIGENE ll Respiratory Flex Assay is a sample-to-answer test that detects 14 viral pathogens, including SARS-CoV-2, and five bacterial pathogens. Using the VERIGENE ll System, extraction, PCR, and detection all take place in a self-contained cassette. The VERIGENE II Respiratory Flex Assay is designed for flexible, comprehensive detection of common respiratory pathogens.
More details

Respiratory Pathogen Panel + SARS-CoV-2
NxTAG Respiratory Pathogen Panel + SARS-CoV-2

The NxTAG Respiratory Pathogen Panel + SARS-CoV-2 (NxTAG RPP + SARS‑CoV‑2), developed for use on the NxTAG-Enabled MAGPIX® System, is a qualitative test for the detection of nucleic acids from multiple respiratory viruses and bacteria in nasopharyngeal swabs. The formulation of the assay is identical to NxTAG RPP, with the exception of the additional reagents required for the detection of SARS‑CoV‑2. No changes have been made to the existing NxTAG RPP reagents, reaction conditions, workflow, or software thresholds; therefore, the performance characteristics of NxTAG RPP are still applicable to NxTAG RPP + SARS‑CoV‑2.
More details

SARS-CoV-2 Test
NxTAG CoV Extended Panel

The NxTAG CoV Extended Panel offers SARS-CoV-2 detection using three viral genes (ORF1ab, E gene, and N gene), enabling accurate, reliable results. It is a highly scalable, cost-effective solution that can process up to 96 samples in approximately four hours and was developed for use on the MAGPIX NxTAG-enabled System. It has received Emergency Use Authorization (EUA) from the US FDA and Medical Device Authorization for Importation or Sale for Health Canada.
More details

SARS-CoV-2 Test
ARIES SARS-CoV-2 Assay

The ARIES SARS-CoV-2 Assay is a moderate-complexity, sample-to-answer test that detects SARS-CoV-2 in nasopharyngeal swabs. It allows for minimal hands-on time and an automated workflow deliver results in about two hours. Additionally, exonuclease-sensitive probes for the ORF1ab and N viral genes provide superior specificity.
More details

SARS-CoV2 Antibody Test
xMAP SARS-CoV-2 Multi-Antigen IgG Assay

The xMAP SARS-CoV-2 Multi-Antigen IgG Assay is a multiplex, microsphere-based, highly sensitive and specific assay that detects the presence or absence of antibodies against three different SARS-CoV-2 antigens. By using a combination of robust internal controls and highly-specific antigens, the assay may provide earlier, more sensitive results.
More details
Close

News of Luminex Corporation

DiaSorin Completes Acquisition of Luminex to Become a Full-Fledged Diagnostic and Life Science Player

16 Jul 2021
DiaSorin Completes Acquisition of Luminex to Become a Full-Fledged Diagnostic and Life Science Player
DiaSorin S.p.A. (?Saluggia?, Italy) has completed the acquisition of Luminex Corporation (Austin, TX, USA), allowing it to gain access to Luminex’s multiplexing technology and a portfolio that will strengthen its existing offering, while expanding the Group presence in the US.
Read More

DiaSorin to Acquire Luminex to Broaden Positioning in Molecular Diagnostics Space

13 Apr 2021
DiaSorin to Acquire Luminex to Broaden Positioning in Molecular Diagnostics Space
DiaSorin S.p.A. (?Saluggia?, Italy) has announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation (Austin, TX, USA) for approximately USD 1.8 billion.
Read More
Close

About Luminex Corporation

Luminex develops, manufactures, and markets biological testing technologies with applications in clinical diagnostics, pharmaceutical drug discovery, biomedical research, including genomic and proteomic research, personalized medicine, biodefense research, and food safety. The company’s open-architecture xMAP technology enables large numbers of biological tests (bioassays) to be conducted and analyzed quickly, cost-effectively and accurately.
FaceBook Twitter Google+ Linked in
SARS-CoV2 Antibody Test

SARS-CoV2 Antibody Test

Model: xMAP SARS-CoV-2 Multi-Antigen IgG Assay
Request Information

Description:

The xMAP SARS-CoV-2 Multi-Antigen IgG Assay is a multiplex, microsphere-based, highly sensitive and specific assay that detects the presence or absence of antibodies against three different SARS-CoV-2 antigens. By using a combination of robust internal controls and highly-specific antigens, the assay may provide earlier, more sensitive results.

Tags: [Clinical Laboratory], [Rapid Tests]
Features

Features

• Broad Coverage: Detects IgG antibodies against 3 SARS-CoV-2 antigens, providing comprehensive results:
S1 subunit of the spike protein
Receptor Binding Domain (RBD) of the spike protein
Nucleocapsid protein

• Flexible Throughput: Test up to 96 samples per run in less than 3 hours to meet your throughput needs.

• Versatile System Options: Validated on MAGPIX, Luminex 200, and FLEXMAP 3D Systems, so you can use the platform that best fits your lab.

• Common Sample Types: Designed for use with human serum and plasma samples, eliminating the need to implement additional collection protocols. Request Information

Send A Message To This Supplier

* Required Information
* Email
To
Luminex Corporation (SARS-CoV2 Antibody Test)
* Message

More Products From This Supplier

Molecular Diagnostic Platform
VERIGENE II System
Immunoassay System
FLEXMAP 3D
Cell Analyzer
Guava Muse Cell Analyzer
Respiratory Assay
VERIGENE ll Respiratory Flex Assay
Methicillin-Resistant Staphylococcus Aureus (MRSA) Assay
ARIES MRSA Assay
In Vitro Diagnostic System
ARIES M1
Respiratory Pathogen Panel + SARS-CoV-2
NxTAG Respiratory Pathogen Panel + SARS-CoV-2
Multiplex Reader
Luminex 200
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions